Veterinary Biologicals Biobank Market

By Type;

Veterinary Clinics, Veterinary Companies and Research Institutions

By Product Type;

Frozen biological Samples and DNA/RNA Samples

By Animal Type;

Dogs, Cats, Horses and Others

By Application;

Genetic Research and Disease Studies

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn102544786 Published Date: August, 2025 Updated Date: September, 2025

Veterinary Biologicals Biobank Market Overview

Veterinary Biologicals Biobank Market (USD Million)

Veterinary Biologicals Biobank Market was valued at USD 155.39 million in the year 2024. The size of this market is expected to increase to USD 284.06 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 9.0%.


Veterinary Biologicals Biobank Market

*Market size in USD million

CAGR 9.0 %


Study Period2025 - 2031
Base Year2024
CAGR (%)9.0 %
Market Size (2024)USD 155.39 Million
Market Size (2031)USD 284.06 Million
Market ConcentrationMedium
Report Pages365
155.39
2024
284.06
2031

Major Players

  • Vetbiobank
  • Cornell Veterinary Biobank
  • University of Nottingham
  • IZSLER

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Veterinary Biologicals Biobank Market

Fragmented - Highly competitive market without dominant players


The Veterinary Biologicals Biobank Market is evolving rapidly as veterinary research institutes, pharmaceutical firms, and diagnostic labs emphasize the preservation of animal‑derived biological samples. About 60% of facilities now maintain structured biobanking systems, fueling strong growth driven by rising demands for sample authenticity, traceability, and multi‑year research access. These developments highlight innovation in storage solutions and quality control, creating key opportunities for providers to advance standardized, scalable biobank services and expand market presence.

Advanced Storage and Sample Management
Recent technological advancements include automated cryopreservation modules, AI‑assisted inventory tracking, and temperature‑controlled shipping solutions. Nearly 65% of newly implemented biobank facilities utilize these systems to ensure sample viability and enhance usability across vaccine development, disease surveillance, and genetic research. These improvements help drive expansion by enabling efficient sample management and broad instrumental utility.

Strategic Rollout Fueling Sample Accessibility
Manufacturers and service providers are deploying thoughtful strategies such as centralized sample repositories, remote access platforms, and support programs for research teams. These efforts have led to approximately 70% of veterinary laboratories utilizing branded biobank platforms. These strategies improve sample sharing capabilities and foster ongoing expansion across research networks and pharmaceutical pipelines.

Smart Systems Shaping Future Biobank Services
Looking ahead, the future outlook is centered on innovation in smart biobank systems that integrate blockchain-enabled chain‑of‑custody logs, predictive maintenance sensors, and molecular‑grade storage environments. Over 75% of emerging systems under development aim to include real‑time monitoring of sample integrity and health‑data interoperability. These technological advancements are expected to drive long‑term growth and deeper expansion in veterinary research infrastructure.

In this report, the Veterinary Biologicals Biobank Market has been segmented by Type, Application and Geography.

Veterinary Biologicals Biobank Market, Segmentation by Type

Veterinary Clinics

Veterinary clinics lead sample sourcing for biobanking through routine diagnostics and follow-ups, making up around 35 % of industry activity. These clinics, especially in urban centers, offer streamlined access to companion animals, allowing seamless collection and storage of specimens. With rising awareness of pet genomics and preventive healthcare, their participation in veterinary biological repositories continues to grow, enhancing the real‑world data focus of the sector.

Veterinary Companies

Contributing approximately 40 % of the market, veterinary companies—including biotech firms, animal health product developers, and diagnostic service providers—maintain dedicated biobank infrastructures. They preserve samples for vaccine and therapeutic development, employing stringent quality controls, traceability systems, and scale operations. Their deep integration with R&D pipelines positions them as vital drivers of the veterinary biobanking ecosystem.

Research Institutions

Accounting for around 25 % of utilization, research institutions—such as academic centers and government labs—harness biobanks to fuel genetic studies, pathogen surveillance, and animal disease research. Partnerships with clinics and companies amplify access to varied specimen types. Their data‑driven investigations support breakthrough discoveries and policy intelligence, shaping future directions in veterinary science and health strategies.

Veterinary Biologicals Biobank Market, Segmentation by Application

The Veterinary Biologicals Biobank Market has been segmented by Application into Genetic Research and Disease Studies.

Genetic Research

Accounting for about 45 % of biobank usage, genetic research is a critical focus in veterinary biological repositories. These biobanks underpin genome sequencing, trait inheritance mapping, and interspecies genetic comparisons. By furnishing precise genetic insights, they enable veterinary researchers to unveil breed‑specific vulnerabilities and support evidence‑based breeding initiatives. The adoption of bioinformatics frameworks and unified data collection protocols ensures high accuracy and repeatability across studies.

Disease Studies

Occupying roughly 55 % of the veterinary biobanking market, disease studies represent the dominant application segment. Biobank specimens are instrumental in investigating animal infections, zoonotic threats, and assessing vaccine responses. With access to longitudinal and geographically varied samples, researchers can monitor disease outbreaks, improve diagnostic assays, and develop robust health interventions. Strategic collaboration among biobanks, veterinary clinics, and research institutions ensures the advancement of disease modeling and public health policy insights.

Veterinary Biologicals Biobank Market, Segmentation by Geography

In this report, the Veterinary Biologicals Biobank Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America

Regions and Countries Analyzed in this Report

Legend
North America
Rest of North America
Europe
Rest of Europe
Asia Pacific
Rest of Asia Pacific
Middle East and Africa
Rest of Middle East and Africa
Latin America
Rest of Latin America
Rest of the World

Veterinary Biologicals Biobank Market Share (%), by Geographical Region

North America

North America dominates the Veterinary Biologicals Biobank Market with roughly 32–37 % share, thanks to its mature veterinary research infrastructure, high pet ownership levels, and well‑funded biobanking networks. Rigorous regulatory frameworks and strong public–private coordination strengthen sample standardization and long‑term storage initiatives, making it the market leader.

Europe

Europe holds about 36–37 % of global market share, underpinned by comprehensive biobank integration across academic institutions, hospitals, and veterinary labs. EU‑backed projects enable centralized access to diverse specimen collections, while harmonized regulations support consistent data quality and cross‑border research collaborations.

Asia Pacific

Though currently smaller in share, Asia Pacific is the fastest‑growing region, driven by increasing veterinary healthcare spending, government support, and investments in biotechnology centers across China, India, and Japan. Its rapid expansion is reshaping the global veterinary biobank landscape.

Middle East & Africa

Capturing about 1.7 % of the global biobanking market, the Middle East & Africa are emerging regions with limited infrastructure. Growth prospects stem from expanding government and private sector initiatives, particularly in the UAE, aiming to build biobank capacity and elevate scientific contributions.

Latin America

Latin America currently holds a modest market presence but is developing steadily through enhanced veterinary health initiatives, rising academic biobanking interest, and expanding disease surveillance programs. While quantitative regional share is unpublished, it occupies a meaningful portion of the emerging‑market segment.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Type
    2. Market Snapshot, By Product Type
    3. Market Snapshot, By Animal Type
    4. Market Snapshot, By Application
    5. Market Snapshot, By Region
  4. Veterinary Biologicals Biobank Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Research Advancements
        2. Growing Focus on Animal Health
        3. Demand for Precision Medicine
        4. Regulatory Support
      2. Restraints
        1. Ethical Concerns
        2. Cost of Operations
        3. Limited Funding
        4. Technical Challenges
      3. Opportunities
        1. Emerging Markets Expansion
        2. Collaborative Research Initiatives
        3. Advancements in Biobanking Technology
        4. Rising Demand for Rare Disease Research
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Veterinary Biologicals Biobank Market, By Type, 2021 - 2031 (USD Million)
      1. Veterinary Clinics
      2. Veterinary Companies
      3. Research Institutions
    2. Veterinary Biologicals Biobank Market, By Product Type, 2021 - 2031 (USD Million)

      1. Frozen Biological Samples

      2. DNA/RNA Samples

    3. Veterinary Biologicals Biobank Market, By Animal Type, 2021 - 2031 (USD Million)

      1. Dogs

      2. Cats

      3. Horses

      4. Others

    4. Veterinary Biologicals Biobank Market, By Application, 2021 - 2031 (USD Million)
      1. Genetic Research
      2. Disease Studies
    5. Veterinary Biologicals Biobank Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Vetbiobank
      2. Cornell Veterinary Biobank
      3. University of Nottingham
      4. IZSLER
  7. Analyst Views
  8. Future Outlook of the Market